ROVI CDMO Business Unit rebrands as ROIS and Expands with New Phoenix, Arizona Injectable Manufacturing Facility

[Madrid, Spain – September 29, 2025] – ROVI CDMO Business Unit, a leader in injectable manufacturing, today announces two major milestones: the company will rebrand as ROIS and has agreed to acquire a state-of-the-art injectable drug product manufacturing and packaging site in Phoenix, Arizona (USA) from Bristol Myers Squibb.

This strategic move establishes ROIS as a global Contract Development and Manufacturing Organisation (CDMO), expanding its capabilities and enabling direct US-based production while continuing to strengthen its European operations.

A new brand for a new era
The ROIS brand signals the next stage in the company’s evolution. ROIS has built a reputation as a trusted partner for injectable development and manufacturing, and the rebrand reflects its continued investment in capacity, technology and service.

“Our transformation into ROIS reflects where we are today and where we are headed,” said Javier López-Belmonte, Vice Chairman of the Board & Chief Financial Officer, “We are proud of our legacy and excited about our future — growing, investing, and expanding capacity to meet our partners’ needs worldwide.”

Significant US manufacturing capability
The Phoenix facility comprises approximately 34,000 m² on an ~80,000 m² site and has benefited from ~$100m CAPEX since 2021. The site includes a cytotoxic/high-potent (OEB5) area and holds regulatory approvals from FDA, EMA and Japanese authorities. ROIS plans to install an Optima pre-filled syringe (PFS) isolator line in 2027, projected to add ~65–70 million PFS capacity annually once operational. The US facility is equipped for commercial-scale sterile fill-finish and packaging across vials, PFS and cartridges.

With this expansion, ROIS will:

• Increase global capacity and flexibility for injectable development and production.
• Provide direct US-based manufacturing for pharmaceutical and biotech partners.
• Reinforce its commitment to innovation and investment in advanced facilities and equipment.

The rebrand and US expansion underline ROIS’s vision to be a partner of choice for injectable medicines worldwide, underpinned by continued investment in people, technology and infrastructure.

“This acquisition is a strategic step in building ROIS as a global CDMO for high-value injectables,” added Javier López-Belmonte, Vice Chairman of the Board & Chief Financial Officer. “The Phoenix site adds significant sterile fill-finish and high-potent capability, enabling us to better serve partners on US soil while continuing to invest across our network.”

For more information, visit www.roiscdmo.com.